$TSOI: NEWS--Therapeutic Solutions International

New Post Public Reply Private Reply Replies (0) Message Board
SHEEPWOLF
752
$TSOI: NEWS--Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients
OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a patent covering its proprietary method of implementing S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act in a manner which provides a novel means of safeguarding patients while allowing rapid access to experimental medications.

The patent application is based on the current Standard Operating Procedures of the Right to Try Foundation, which call for a physical or virtual independent Institutional Review Board assessment of each patient considered for an experimental medication.

"The fact that publicly this new pathway of providing hope to patients with no hope has only been used two times [1] since the law was passed is appalling" said Famela Ramos, President and Founder of the Right to Try Foundation. "Why are American patients with terminal illnesses travelling to hospitals outside the USA when so many experimental treatments are available here? By establishing an independent means of ensuring patients are protected, we believe that we solve the issue that many opponents of the law raise, which is that patients will be victims of predatory companies."

The Right to Try Foundation seeks to accelerate medical progress by establishing means by which drugs that are demonstrated safe can be used for different diseases or in combinations with other drugs based on the ideas of the doctors and not the Pharmaceutical Companies.

Therapeutic Solutions International has a filed Investigational New Drug (IND) application for StemVacs™ a novel Cell Based Cancer Immunotherapy [2] that specifically trains the immune system to kill cancer stem cells.

"Immunotherapy is the greatest advancement in the area of clinical oncology," said James Veltmeyer, MD, Chief Medical Officer of Therapeutic Solutions International. "To our knowledge, StemVacs™ is the only clinical stage immunotherapeutic that kills cancer stem cells. This, combined with the safety and signals of efficacy obtained from the current Phase 1 clinical trial, support us to expand the use of StemVacs™ under President Trump's recently passed Right to Try Law. I applaud Timothy Dixon and Famela Ramos for this joint collaboration leading to a new pathway to take drugs into the clinic with an added level of safety."

"We have highly benefitted from working with the Right to Try Foundation in terms of establishing necessary procedures and systems to not only utilize this new law but to collect data in a Good Clinical Practices compliant manner, said Timothy Dixon, President and CEO of Therapeutics Solutions International. "Our Phase I safety data motivates us to continue clinical development of StemVacs™, of which part of the development pathway absolutely includes providing patients access to it now under the Right to Try Law and we are very excited to continue our work with Right To Try Foundation."

About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

[1] https://www.raps.org/news-and-articles/news-a...ient-invol
[2] http://www.stemvacs.com

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc.
ir@tsoimail.com


Source: Therapeutic Solutions International, Inc.
https://www.otcmarkets.com/stock/TSOI/news/st...id=1409711
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 93

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 165

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 64

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 49

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading

Top 5 Most Recently Viewed Articles

AlidaBio Unveils New Platform to Revolutionize RNA Research

Updated Category News Views 249

Introducing the EpiPlex™ Platform Alida Biosciences, known for its innovative tools in epigenomic research, has officially launched its EpiPlex™ platform. This groundbreaking technology stands out by being the first to detect and quantify multiple RNA modifications concurrently, using short-read sequencing. Alongside this platform, the company has introduced the...

Continue Reading
Kootenay Silver Welcomes Ron Miller to Its Board of Directors

Updated Category News Views 149

Kootenay Silver Welcomes Ron Miller to Its Board of Directors Kootenay Silver Inc. (TSXV: KTN) (OTCQX: KOOYF) proudly announces the appointment of Ron Miller as a new director. With over 30 years of rich experience in public accounting and the mining industry, Mr. Miller brings a wealth of expertise to the company. Previously, he was a Partner and National Leader in...

Continue Reading
Estee Lauder Options Trading Insights and Market Position

Updated Category News Views 48

Unusual Options Activity for Estee Lauder Cos Recently, a noticeable shift has occurred in the options trading landscape for Estee Lauder Cos (NYSE: EL). Our analysis has identified some significant bearish actions from prominent financial investors targeting this beauty giant. Out of a thorough review of options trading history for Estee Lauder Cos, a total of ten...

Continue Reading
Roche's Innovative PCR Test Enhances Vaginitis Diagnosis for Women

Updated Category News Views 217

Roche Introduces Groundbreaking PCR Test for Vaginitis Roche has recently launched an innovative PCR test aimed at enhancing the diagnostic accuracy for women dealing with vaginitis. This new assay, named cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis), harnesses the power of advanced molecular technology to identify specific bacteria and yeast linked to these...

Continue Reading
Regan Capital Offers New Fee Structure for Income Fund Investment

Updated Category News Views 155

Regan Capital Announces Fee Reduction for Its Income Fund Regan Capital, a prominent investment firm overseeing more than $2.2 billion in assets, has made a significant announcement that is sure to capture the attention of investors. The firm revealed a fee reduction for its acclaimed Regan Total Return Income Fund, known by its ticker RCIRX. This open-ended mutual fund...

Continue Reading